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Abstract  
Background: Streptococcus  pneumoniae, the pneumococcus, is major human pathogen that 
causes more than 820,000 deaths worldwide annually, especially in developing countries. The 
most diseases presentations are acute respiratory tract infection (ARTI), otitis media, septicemia 
and meningitis. Pneumococcal meningitis has a higher fatality rate than meningitis caused by 
other bacteria. On the basis of the capsular polysaccharide type of the cell wall, can be serotyped 
into  more than 90 serotypes. It is a vaccine preventable disease, and several vaccines based on 
different combinations of capsular component have been developed. The serotype distribution of 
this organism differs by geographical areas and the prevalent serotypes in one region could not 
necessary be the basis for vaccine formulation for another. Thus, it is essential to know the 
epidemiology and prevalence of the different serotypes. 
Methods: To characterize pneumococcal strains in Ethiopia among diagnosed for pneumococcal 
infection by the physician and referred to the clinical microbiology laboratory of selected health 
institutions in Addis Ababa and Gondar from July to December 2012. All samples were cultured 
on appropriate  culture media and typical pneumococcal colonies were confirmed by biochemical 
tests. Antibiotics resistance test was done by E-test strips and  interpreted according to European 
guidelines. Serotyping was done by Quellung reactions,  and  isolates were characterized by 
multilocus sequence typing (MLST)  to determine phylogenetic classification. Culture negative 
CSF from pyogenic meningitis were tested  by Real time PCR.  
Results: A total of 460 samples were collected, sixty one pneumococcal isolates were identified 
and most of them from cerebrospinal fluid (CSF). 15 serotypes were identified, with serotype 1 
(21%) being the leading followed by 19F , 20  (10%) and 14 (8%). In seven samples more than 
one serotype were identified. Predicted coverage of 10 valent vaccine is 44%. Twenty four 
isolates  were intermediate resistant for penicillin and except, for one and three all of them were 
susceptible to ceftriaxone and chlorampheinicol respectively. Seven new sequence types  were 
identified by MLST. From  140 culture negative CSF, 12  were positive for meningococcus 9 for 
pneumococcus  and 2 were mixed.  
 Conclusion: This study has a contribution evaluating the current vaccine program in the 
country.  
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Chapter one:   Introduction 
1.1. Pneumococcal disease 
The Gram-positive bacterium Streptococcus pneumoniae (pneumococcus) is the main cause of 
multiple disease conditions such as community acquired pneumonia, meningitis, otitis media, 
endocarditis, osteomyelitis, pericarditis , pyogenic arthritis , soft tissue infection , early-onset 
neonatal septicemia, lower respiratory infection and  bacteriemia ,  all over the world, but  
especially in developing countries  (1).  According to the World Health Organization , the 
organism is causing more than 800,000 deaths per year  (2).  
 
The pneumococcus is a normal nasopharyngeal inhabitant which can live without clinical 
manifestation on the host and causes  disease occasionally  (3).  Pneumococci  spread by air 
droplet from person to  person through coughing or sneezing and close contact with individuals 
who are carriers or infected.  Pneumococcal transmission can be influenced by social and health 
factors,  such as crowding ,  season,  and viral respiratory co-infection.  During the winter season 
the prevalence of pneumococcal disease increases in most places,  especially in colder areas. 
Young children who are under the age of five and attending day care center, as well as  the 
elderly are more susceptible to pneumococcal infections. Pneumococcal outbreaks may occur,  
for example  in crowded  jails and nursing homes. Immune - compromised individuals with 
HIV/AIDS or other chronic medical conditions  such as heart or lung diseases and asplenia  are 
at high risk of acquiring pneumococcal infections   (4, 5).  
 
1.2  Classification of the genus Streptococci 
a) The genus Streptococci 
The genus Streptococcus includes a group of bacteria that are medically important as well as  
some commensal bacteria. They are Gram -positive cocci in chain or pairs, non motile, non spore 
former, facultative anaerobic, catalase negative and some are encapsulated. Fastidious they can 
grown on culture media supplemented with 5% sheep or horse blood  under CO2 atmosphere  (6).  
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This group of bacteria is subdivided on the basis of their hemolytic characteristics on blood agar, 
serologically based on the specific carbohydrate or group antigen,  fermentation and tolerance 
tests, and sequencing of the 16S rRNA gene.  The diagnosis of Streptococci In the clinical 
bacteriology laboratory, the diagnosis of Streptococci relies on the breakdown of red blood cells 
(6, 7) .  According to their hemolytic characteristics they can be grouped as  beta-hemolytic 
streptococci,  which lyse red blood cells completely, alpha-hemolytic or partial hemolytic,  and 
gamma-hemolytic streptococci which are non hemolytic. Serologically,  beta-hemolytic 
sreptococci can be differentiated by the presence of group specific antigens that might be C- 
carbohydrate or teichoic acid. By this classification,  or Lancefield grouping,  they can be 
grouped A to V. Bacteria such as  S.  pneumoniae and viridians group of streptococci that lack C-
carbohydrate or M protein cannot be classified by this method. The ability to ferment 
carbohydrates and tolerance to salt concentration or pH change are also used for classification. 
The current and most reliable method of classification is by gene sequence analysis  the resulting  
phylogenetic tree. Around 99 groups of streptococci are recognized on the basis of 16S rDNA 
sequences and the main ones include : S. pyogenes, S. agalactae, S. equismilis, S. bovis,  S. 
sanguis ,  S. swis , Viridians Streptococci.  The viridians Streptococci contains Mitis, Mutans, 
Salivarius and Anginosus  (8).   
b) Phenotypic differentiation of S. pneumoniae 
S.  pneumoniae belongs to the Mitis group. It is alpha hemolytic and has no group antigen. The  
bacterium measures 0.4 μm in width and 1 to 1.5 μm in length. It is the leading cause of 
pneumonia and the morphology of the organism, respectively. The organism needs catalase 
containing media, produces pneumolysin (formerly called haemolysin) which breaks down 
hemoglobin into a green pigment. As a result pneumococcal colonies are surrounded by a green 
zone during growth on blood agar plates. Fermentation of monosaccharides, (glucose, mannose, 
fructose and galactose),  disaccharides, (sucrose, lactose, trehalose, maltose and cellobiose) 
trisaccharide, (raffinose)  or a fructose oligosaccharide (inulin) can distinguish them  from other 
species (8, 9, 10).  
To differentiate S. pneumoniae  from other viridians streptococci which have similar hemolytic 
character and belong to the   normal human nasopharyngeal flora, optochin (ethylhydrocupreine ) 
susceptibility test or bile solubility tests are used. A  simple method is observing an inhibition 
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zone of 14 mm or more around an optochin disk. The bile solubility test is performed by  
observing the clearance of turbidity of sodium deoxycholate  after two hours incubation at 37
o
C. 
All suspected pneumococcus with inhibition zone of  10-13 mm diameter by optochin test should 
be confirmed by bile solubility test.  Other  viridians  are negative in the optochin test and do not 
clear sodium deoxycholate after two hours incubation at 37
o
C (9).  
 
1.3   Cell wall composition and serotyping  
Like other Gram positive organisms, the pneumococcus has a cell wall containing a 
peptidoglycan layer and teichoic acid in larger amount ( Figure 1).  The polysaccharide 
substance (Slime layer) around the cell wall secreted by the bacterium,  becomes thick and forms 
a capsule. The cell wall is covered by a polysaccharide capsule that is immunogenic and its 
polysaccharide composition differs among strains.  The capsular antigenic component of the 
organism is used to divide into serotypes.  
 
Figure 1 Pneumococcal cell wall (38) 
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1.4 Laboratory methods to verify and characterize S. pneumoniae 
a) Standard methods for laboratory isolation methods of S. pneumoniae 
Pneumococcus can be identified  by different types of laboratory techniques. These include the 
simple and rapid technique of Gram stain to the complicated method of  identification of the 
organism at the gene level. The simplest method is observing Gram positive cocci in pair under 
the microscope from a clinical sample. The gold standard is the culture method,  isolating live 
organisms and doing further identification as described above and antimicrobial susceptibility 
test  ( 9, 10).   
 
b) Serotyping 
The Quellung reaction is based on the swelling of the pneumococcal capsule. Upon binding  with 
homologous antibody the capsule surrounding the bacterium swells and become visible under the 
microscope.  Swelling and aggregation of cells indicates a positive reaction for the serotype 
specific antibody. On the basis of variation in capsular components, currently there are 94 
serotypes identified  (11 ) .  
 
c) Antimicrobial susceptibility testing 
A predefined antimicrobial gradient concentration on a plastic strip can be used to determine the 
minimum inhibitory concentration (MIC) of antibiotics. The antibiotic on the strip will diffuse in 
the agar plate on which bacteria are inoculated and inhibits the growth. After overnight 
incubation at 37
o
C, MIC can be interpreted  (12).  
 
1.5  DNA based detection and characterization 
a. Conventional PCR 
This method is used for detecting bacterial pathogens from clinical samples if the culture test 
negative due to prior antibiotic treatment or cell lysis.  To do this test, polymerase enzyme, 
primer or strand of DNA to start synthesis, dNTP which are building blocks of DNA and single 
or few copies of the targeted DNA are required.  It has three steps; first the double strand DNA 
will be denatured and become single strand,  followed by annealing of primes with 
complementary single strand of targeted DNA then extension of primers 5' to 3'  direction by 
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polymerase enzyme and double stranded DNA will be produced. This cycle repeats many times 
and   at every extension step DNA molecules would be doubled and finally thousands or millions 
of targeted DNA will be amplified. At the end  of DNA amplification, the PCR product will be 
detected, visualizing  under UV light running agarose gel electrophoresis   (13).  
 
b. Real Time PCR 
Real time PCR is modified version of conventional PCR that detects based on fluorescent dies. 
This is also another molecular detection but more sensitive and fast detecting bacterial pathogens 
from clinical samples. It is a kinetic method which amplifies  and detects targeted genes 
simultaneously. There are two types of RT-PCR: non- specific and specific ones. The non 
specific one uses fluorescence dye that intercalates in to any double stranded and emits light. The 
specific one uses probe which contains nucleotides labeled with  fluorescent reporter which 
emits resonance energy to a quencher  when it reacts  with its complementary DNA target.  The 
targeted gene is lyt A gene which is common for all clinical pneumococcal  isolates  (2, 14). 
 
c. MLST 
 
Multilocus sequence typing (MLST) is based on amplification and sequencing of  seven 
housekeeping  genes which are common for all clinical isolates of pneumococcus. This method 
is used to identify the genetic diversity of clinical isolates and their phylogenetic relationships  
(15).  
 
 
1.6. Serotype distribution among S. pneumoniae  
 Out of the 94 serotypes identified,   20 to 25  are the commonest causative agents of 
pneumococcal infections.  while the remaining ones usually live commensally (16).   The 
distribution of the serotypes may differ in different geographical locations, season, immune 
status of the individual and age group of the host. The main clinical manifestations against 
different serotypes may also differ. (17) 
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a) Geographical distribution of serotypes 
The pneumococcal serotype distribution is different in industrialized countries and developing 
countries. Serotypes:14,  4, 1, 6A, 6B, 3, 8, 7F, 23F, 18C, 19F, and 9V are the most  frequent in 
decreasing order all over the world and are together the cause for more than 80% of the global 
pneumococcal burden  (16).  In North America, the serotype distribution is (14,  6B/  A, 19F/ A, 
18C / B/ F, 23F / B / A,  4, 7F,  3, 1, 15C / B/ A  and 12. In Europe the serotype distribution is 
similar to that in North America with only a slight differences.  In Africa the  serotype 
distribution differs with in decreasing order : 6B/ A, 14, 1, 19F/ A, 23F, 5, 15,18F/ A, 4, 7F/ A, 
9N/ L and 8. Serotype 14 causes most cases of invasive bacterial disease (IPD) followed by 6B 
and 6A  (18). 
 
A study conducted in the Gambia, West Africa, indicated that the commonly identified  
serotypes from IPD cases  were 1, 5, 14, 6A, 19A, and  23F (18).  Another study conducted in 
countries of the East African region by netSPEAR identified serotypes 1, 6B, 14,  6A,  23F, 19A 
as the most  frequent  (19).    
 
b) Age 
Children under the age of five and elderly above sixty are more vulnerable for pneumococcal 
infections. In developed countries pneumococcal infections are more prevalent in the elderly 
whereas in developing countries young children are more affected. The serotype distribution 
varies among different age groups.  Serotypes 14, 6B, 1, 19F, 23F are more frequent among 
young children, with serotype 14 being the leading cause of pediatric pneumococcal infection. 
Serotype 1 is more isolated from children between the age of one and five than children below 
the age of 2  (17, 20). 
 
1.7. Carriage of S. pneumoniae 
S. pneumoniae has no environmental reservoir;  and humans are its only reservoir.  The organism 
colonizes the human nasopharynx  within the first year of life. More than one serotype could 
colonize the same host at the same time and live together. the host may become a source for 
horizontal transmission or the carriage may end up to a year. The carriage rate is more prevalent 
in young children under the age of five who have poorly developed immune system. On the other 
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hand followed by the acquisition of the pneumococcus the host carrying the organism for a long 
time, may produce serotype specific antibodies and clear the organism within a couple of weeks  
(22).  The carriage rate decreases in  the adulthood period. The carriage rate can increases up to 
40 to 60% in children and up to 10 to 15 % in adulthood  (21). 
 
After colonization in the upper respiratory tract the bacterium  can cause local or  systemic 
pneumococcal diseases. Clinical manifestations depend on the inoculums size and the  virulence 
of serotypes (22).  
 
1.8. Risk factors for pneumococcal infection 
Both  host and environmental factors can aggravate the infection of pneumococcus. The host 
factors associated with high risk for pneumococcal disease include: viral upper respiratory tract 
co-infection, abnormal epithelial cells at the upper respiratory tract, immune status (chronic 
disease, immune-compromised) and extreme age groups. Environmental factors include airborne 
pollutants like tobacco or indoor fire cooking and heating, crowded living condition as in jail or 
nursing home, and living in cold areas  (23).  
1.9. Pathogenesis, pathology and virulence factors 
 
The portal of entry for the organism is through the upper respiratory tract of humans. It can cause 
respiratory infection in this niche, as well as migrate to a variety of niches and cause deprived 
types of disease including otitis media, community acquired pneumonia, septic arthritis, 
septicemia and meningitis. Around 25% of community acquired pneumonia is caused by 
pneumococcus; especially , it is the leading cause of pneumonia among HIV positive individuals. 
The organism has different mechanisms to colonize the host as well as to cause disease. Genetic 
and physical components of the bacterium play great role in pathogenesis  (24).  
The first step of pathogenesis is adherence to the host cell. The organism adhere to the mucosal 
epithelial cells of the nasopharnyx using N- acetyl galactosamine β 1-3 galactose (GlcNAcβ1-
3Gal) disaccharide receptor on the host epithelial cell. The pneumococcal surface protein or 
choline binding protein A CbpA is exposed to the external surfaces and attaches with the 
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nasopharyngeal epithelial cells. Some non specific factors also enhance the adherence of the 
organism with the host receptor cells. These factors include hydrophobic interaction between 
cells of the host and the bacterial cell, surface charge and  pH. (25)    
 
1.10   Virulence factors 
The pneumococcus possesses  different virulence factors that are mandatory to escape the host 
immune response during  infection. Pneumococcal infection and its complications result partly 
from the direct actions of pneumococcal virulence factors and the corresponding immune 
responses to various pneumococcal components resulting in adhesion, invasion, inflammation 
and shock . Pneumococcal virulence factors mainly include: 
 
 
Table 1. Major pneumococcal virulence factors and their function  
Virulence Factor  Function Reference 
IgA protease Cleaves human IgA1, preventing   antibodies from 
inhibiting adhesion. 
26 
Cell wall Releases inflamatory response  10, 26 
Surface protein (Pneumolysin) Pore formation on host cell membrane, enhances 
pathogenicity 
24 
Hyaluranidase Degrades connecting tissue  27 
Capsular polysaccharide Prevents  the organism to be removed by innate 
immunity.  
10, 26,29 
Pilli  Binds  with host cells  28 
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 Capsular polysaccharide:.  
The polysaccharide capsule is the main virulence factor, used to colonize the host and prevents 
the removal of pneumocccus by innate immunity. This also protects the organism from 
phagocytosis by leukocytes following opsonization inhibiting the C3b complement system.  (10, 
25, 26) 
 
1.11. Treatment and antimicrobial susceptibility pattern 
 
Pneumococcal infections can be cured by antibiotic treatment. Traditionally penicillin was the 
drug of choice. All patients diagnosed with pneumococcal disease were empirically treated by 
penicillin. (30) But after the first reports of penicillin resistant pneumococcus, in 1967, from 
Australia and then from Papua New Guinea and  South Africa, resistance all over the globe 
become a problem and antibiotics other than penicillin had to be used. (31 ) Currently, multi drug 
resistant pneumococci are spreading all over the world and become a great public health concern. 
(32) 
Improper taking of antibiotics without prescription and improper dose select for resistance. 
Prescribing antibiotics as a prophylaxis can also create antimicrobial resistance. A study 
conducted in Ethiopia, indicated that individuals who were treated by azithromycin for trachoma, 
have acquired resistant strains of pneumococcus, compared with placebo groups who did not. 
(33)  The antimicrobial resistance could be by mutation or horizontal exchange of genes between 
non related bacteria via transformation . Often  pneumococcal isolates from the respiratory tract 
have a high rate of antimicrobial resistance due to horizontal exchange from the nasopharyngeal 
flora. For resistance to  penicillin the pathogen alters the penicillin binding site of the penicillin 
binding proteins which leads to low affinity of penicillin and other beta-lactam antibiotics. (2, 
32) 
The fatality rate of pneumococcal infections caused by resistant pneumococcus could reach up to 
50% even under care. To avoid such problems treating pneumococcal infections according to the 
microbiological findings is mandatory for better therapeutic outcome or preventing the spread of 
resistant isolates through the community. Identifying the antimicrobial susceptibility pattern of 
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isolates would have a great role on reducing the fatality rate caused by the organism, as well as 
social and economic impact.(35) 
Currently,  the burden of antimicrobial resistance is very high all over the world including the 
developing countries. Antimicrobial resistance is specific for some strains of pneumococcus and 
serotypes 6A, 6B, 9V, 14, 19F, 23F are responsible for most of the resistance to penicillin and 
other related antibiotics. During the era of vaccine, another challenges is  that strains not covered 
by the vaccine may replace vaccine strains become more resistant to antibiotics that are primary 
choices for the treatment of pneumococcal infection. (34, 36) .   
 
  1.12. Prevention 
 
Pneumococcal infections are vaccine preventable, and  polysaccharide vaccines have been 
developed. However,  antibodies which are produced against one serotype are specific for that 
serotype and cannot induce immunity against other serotypes.  The serotype distribution of this 
organism, differs by geographical areas and the prevalent serotypes in one region are  not 
necessary by a vaccine designed for another region.  To be effective the vaccine  should contain 
serotypes that circulate in the specific community otherwise the outcome will not be that much 
significant. (10)  
Different types of pneumococcal vaccines are produced and licensed. The first polysaccharide 
pneumococcal vaccine was produced around 1940s but licensed in 1977 and used in the United 
States first 1983. It contained purely polysaccharide capsule of 23 serotypes (1, 2 , 3 ,4 ,5 , 6B , 
7F ,8 , 9N ,9V ,10A ,11A ,12F ,14 ,16B, 17F, 18C, 19A, 19F, 20, 22F, 23F and 33F). This 
vaccine is used for susceptible groups, like elderly and immune- compromised individuals, but it 
is not immunogenic for children under the age of two.(37) 
 
A seven - valent pneumococcal conjugated vaccine (PCV-7) was produced in the year 2000. This 
vaccine contains seven pneumococcal serotypes (4, 6B, 9V, 14, 18C, 19F and 23F) which are the 
most prevalent in North America and Europe. This  heptavalent vaccine covered more than 80% 
of the pneumococcal burden in the region. This vaccine was immunogenic enough to induce 
antibody in younger children due to the conjugated meningococcal protein.  Introduction of 
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PCV-7 has limited value for developing countries, however,  due to the lack of additional 
serotypes 1and 5 which are frequent in these nations.  Including three more pneumococcal 
serotypes (1, 5, and 7F), the PCV-10 vaccine was produced in 2009 by Glaxo-Smithkline. 
Around 2010 , including another six more pneumococcal strains to PCV-7 (1,3, 5, 6A, 7F and 
19A), the  PCV-13 vaccine was produced and licensed (38, 39 ).  
 
The PCVs have  a great role in reducing the pneumococcal  disease burden, as they are more 
immunogenic than the polysaccharide vaccine in all age groups.  Especially,  the PCV-13 may 
reduce antimicrobial resistance by preventing the more resistant strains,  like 19A, and 6C (by 
cross protection). Currently, PCV-7 is replaced by PCV-13. The vaccine should be given to  
individuals in  high risk groups.  Before introduction of vaccine for intervention program, there 
should be evidence-based data which can determine the characteristics of pneumococcal isolates 
based on their capsular serotype which circulate in the community. The conjugated 
polysaccharide capsule should cover at least 60-80% of strains causing invasive disease (39, 40).  
 
1.13  Pneumococcal disease in Ethiopia and rational for the study 
a) Pneumococcal disease and vaccination program in Ethiopia 
Ethiopia is located at the horn of Africa bounded by Eritrea to the north, Kenya to the south, 
Somalia and Djibouti to the east and Sudan and South Sudan to the west.  It has a land area of 
1,104,300sq km and with 85 milion people of more than 80 ethnic groups. The capital is Addis 
Ababa which is the largest city , with a population of more than 4 million. Most people live at 
the countryside,  with only 17% urban population  (41).  
In Ethiopia communicable diseases are most common due to climatic variation, poor sanitary, 
and inaccessibility of health facilities, in spite of awareness. The child mortality rate 123/1000  
(42).  Currently more than 30,000 health extension workers are trained and deployed in rural 
areas. Their training is based on disease prevention policy. They are trained on health packages 
of maternal health, child health, reproductive health, and others to have a primary health service 
in the community. 
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Ethiopia is one of the countries severely affected by pneumococcal infections. However, 
although there are reports of clinically suspected cases of pneumococcal disease there are no 
laboratory- confirmed cases reported officially to the World Health Organization (WHO)  ( 43) . 
Knowledge of serotype distribution and antimicrobial susceptibility patterns are important in 
relation to the treatment of pneumococcal disease and vaccination programs.  
PCV-10  was introduced in 2011 for inclusion in national vaccination program although the 
serotypes that circulate in different communities were not known only two studies have 
previously reported on serotype distribution among Ethiopian pneumococcal isolates. (44)  
A study was conducted at the Ethio-Swedish Children’s Hospital in Addis Ababa from 1993 to 
1995. The purpose of the study was to identify the prevalence of pneumococcal and 
Haemophilus serotypes and to study antimicrobial susceptibility pattern. In this study around 46 
pneumococci were isolated and the coverage of  existing pneumococcal vaccines was from  48 to 
65%. This study however had limitations due to a small sample size, and the sample collection 
sites were not adequate. It was also performed two decades ago and more recent studies are 
mandatory in order to generalize for the entire country (35)  
In  2009 there was a report pneumococcal burden in the East African region by The Network for 
Surveillance of Pneumococcal diseases in the East African Region (netSPEAR). The report 
includes 25 pneumococcal isolates from the Black Lion Hospital in Addis Ababa, but there was 
no serotype result due to lack of preserved live organism. The netSPEAR data includes only 
Kenya, Tanzania and Uganda. To fill the gap current and updated data are essential. (19) 
 
b)  Rationale for this study 
Generating data on the Ethiopian pneumococcal serotype distribution and their antimicrobial 
susceptibility pattern can give appropriate information for policy makers. The data that can be 
obtained  from this study will be components to strengthen the current pneumococcal 
immunization program or identify the gap. It would be part of the solution for current program or 
could be components for future studies.    
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Chapter two:  Objective 
 
2.1 General Objective 
To determine the serotype of pneumococcal strains which circulate in Ethiopia and their 
antimicrobial susceptibility pattern.  
2.2 Specific Objective  
To isolate pneumococcal strains from clinical samples 
To perform antimicrobial tests on pneumococcal isolates 
To identify the serotype distribution among the pneumococcal isolates 
To identify the genotype distribution among the pneumococcal isolates and relate to serotypes 
and antimicrobial susceptibility results 
To provide information for policy makers relevant for drug use policy and vaccination programs 
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Chapter three:  Materials and methods  
3.1.  Study design  
The study design was cross sectional study.  
3.2. Target population  
The target population was all individuals who were clinically suspected for pneumococcal 
infection like meningitis, pneumonia, septicemia,  especially children 59 months
 
of age and 
elderly greater than the age of 60.  
3.3.  Study sites 
The  Black Lion (Tikur Anbessa) Hospital, Addis Ababa, is the largest teaching hospital for the 
University of Addis Ababa Medical School in Ethiopia, with about 800 beds. It is staffed by 130 
specialists and 50 non-teaching doctors. The emergency department sees around 80,000 patients 
a year. 
 
The University of Gondar Hospital,  Gondar, Amhara region is a 400 bed university hospital, 
which acts as the referral centre for four district hospitals in the area. It has a range of specialties 
including pediatrics, surgery, gynecology, psychiatry, HIV care and an outpatient clinic. Within 
its 400 staff it employs 50 doctors, 150 nursing staff, three pharmacists, 90 care staff and 25 
laboratory scientists. These staffs serve a population of four million across the region. As a 
university hospital, it plays an important role in teaching medical and nursing students. 
 
Yekatit 12 Hospital is a referral hospital in the capital Addis Ababa. It gives service for clients 
who are referred from public or private health institutes in Addis Ababa. It has pediatrics, 
surgery, gynecology, psychiatry, HIV care and an outpatient clinic.  
 
 
The St Paul Millennium Medical College Hospital is a specialized general hospital located in 
Addis Ababa,  next to the Ethiopian Health and Nutrition Research Institute (EHNRI). It has 
pediatrics, surgery, gynecology, psychiatry, HIV care and an outpatient clinic. Usually,  most 
microbiology tests from the hospital are referred to EHNRI.  
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The Addis Ketema Health Center and Wereda 7 Health Center are found in the capital city at the 
sub city of Addis Ketema. Selam Health Center is also located in the capital city at Gulele sub 
city. Each health center has around 250, 000  catchment population and provides an  outpatient 
clinic, mother -child health service, and HIV care and follow- up for TB patients.  
  
EHNRI is the national reference laboratory located at the capital city Addis Ababa. It conducts 
research on infectious and non infectious diseases, nutrition and food science, traditional 
medicine, regional laboratory capacity building and  diagnostic laboratory  service for patients 
who are referred from public and private health institutes.  
  
Study sites were selected according to pediatric facilities (Senior pediatrician) as well as 
laboratory test available (microbiology culture test availability or vicinity to the microbiology 
laboratories).  
 
 
Figure 2 Map that shows study sites in Ethiiopia (45)  
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3.4.  Sample size and sampling strategy 
By convenient sampling method all individuals with sign and symptoms of pneumococcal 
disease who visited these health facilities during the study period were included in the study. All 
pediatrics CSF suspected for bacterial meningitis from all study sites were included in the study.   
 
Table 2 Sample type and their collection history 
Sample 
type 
History and method for sample collection Collection site 
CSF Suspected meningitis cases of pediatrics unit The PBM study in EHNRI 
Blood  Suspected septisemia  Black Lion  
Throat 
swab  
Suspected of pneumonia Selam Health Center  St Paul 
and Wereda 7 
Sputum Suspected of upper respiratory tract infection  St Paul Hospital, Addis 
Ketema, Wereda 7 and Selam 
Health Centers 
Pleural 
fluid 
Suspected of arthritis cases Black Lion and St Paul Hospital 
Ear swab Pediatic otitis media infection St Paul Hospital and EHNRI 
 PBM= Pediatric bacterial meninigitis surveillance conducted by WHO in collaboration with 
EHNRI. 
 
3.5.  Sample collection period 
The collection period was between July 2012 to December 2012. 
3.6. Inclusion Criteria 
All patients who have been diagnosed for pneumococcal infection by the physician and referred 
to the clinical microbiology laboratory  were eligible for entry into the study.  
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  3.7.  Sample collection  
CSF samples were collected by lumbar puncture  performed by  a well -trained physician. Drops 
of CSF were collected into sterile screw cap tubes with 1 ml of CSF fluid,  the minimum 
required,  and 3 to 4 ml desirable. Within 1 hour of collection the samples were taken to the 
microbiology laboratory. Samples collected outside of the working hour were also inoculated 
into Trans Isolate (TI) media,  which is diphasic  and can preserve fastidious organisms for a 
long time (2, 46).  
Culture negative CSF samples from the university of Gondar were collected in nunc tube without 
preservative and stored at -70
o
C until transport to Norwegian Institute of Public Health (NIPH).  
Throat samples were collected using sterile cotton tipped swabs with Amies charcoal transport 
media, produced by Oxoid. For babies, the mother made the child to open the mouth while the 
physician took the throat sample. The samples were transported to the laboratory within a day of 
collection.   
Blood cultures were collected by well trained laboratory technicians or physicians. The blood 
was drawn up to 10 ml for adults and 1-3 ml for children. Then,  aseptically disinfecting the cap 
of the bottle with 70% alcohol, the blood was added to thioglycolate medium in ratio 1:5  and 
mixed gently by inverting the bottle.  
Pleural fluids were aspirated by well - trained physicians using 18 guage needle with a 10 ml 
syringe.  
Sputum  samples were collected by the patients themselves. They were advised to collect 
morning deep coughing, purulent sputum without saliva in a sterile screw caped sputum cup. 
Middle ear discharges were collected using commercially prepared sterile cotton tipped swab 
with Amies charcoal transport media. The physician took the discharge using sterile cotton 
tipped swab and dipped  into the charcoal to transport to the laboratory  (46, 47).  
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3.8  Identification of the agent 
  3.8.1.   Culture  
As soon as the samples arrived to the laboratory,  CSF and  pleural fluids were centrifuged for 20 
min  at 2000 rpm and the supernatants were removed with a Pasteur pipette and saved for 
serology test.  One or two drops of the sediment was used to prepare a Gram smear and 1 to 2 
drops to streak onto the primary culture media  (5% sheep blood agar and  chocolate agar 
supplemented with Isovital X).  For CSF samples with less than 1 ml culturing and Gram stain 
were made directly without centrifugation. (2) 
Blood culture bottles were incubated at 37
o
C,  and after overnight incubation,  Gram smear and 
subculture onto 5% sheep blood agar were done. Blood culture bottles were incubated further for 
seven days inspecting turbidity visually every day. Finally sub-cultivation was performed at the 
seventh day. 
The streaked plates were incubated under 5 to 7% CO2 concentration (candle jars). After 
overnight incubation S. pneumoniae isolates were identified by colonial morphology and  alpha 
hemolysis. Typical colonies of pneumococcus were confirmed by optochin susceptibility test 
with inhibition zone of 14 mm or above and bile solubility test. (2, 9, 10, 17) Colonies that were 
confirmed by optochin susceptibility and bile solubility tests were put in a vial of Greave's 
solution prepared at NIPH. The vials were stored  at -80
o
C at EHNRI until transport to NIPH. 
Culture negative CSF  n= 196 and preserved pneumococci  n = 61 were sent to NIPH by World 
Courier using dry ice. At NIPH the preserved vials were sub-cultured on 5% sheep blood agar 
and incubated overnight at 5% CO2. 
After overnight incubation fresh colonies were picked up for antimicrobial susceptibility test, 
serotyping by Quellung  test, and DNA preparation for MLST  (15, 48, 49 ) 
3.8.2.  Antimicrobial susceptibility tests 
MIC  of antibiotics were determined by  the E-test method which uses graduated concentration 
of antibiotic on a strip. The culture medium for antimicrobial susceptibility test was Muller 
Hinton Fastidious,  supplemented with 5% sheep blood and 20 µg β-NAD.  A loopful of pure 
pneumococcal culture  was inoculated in Muller Hinton broth and cell density of the suspension 
was measured  with a spectrophotometer  at 0.5  McFarland Standard. Then the medium was 
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inoculated using a sterile cotton swab by the machine for even distribution on the plate. 
Antimicrobial strips were put on the media automatically by the machine and incubated into 5% 
CO2 at 37
o
C overnight. After overnight incubation the MICs  were observed and interpreted with 
80% colony inhibition for bacteriostatic antibiotics and clear zone for bacteriocidal antibiotics. 
The antibiotics tested were penicillin G (PG),  ceftriaxone (TX), erythromycine (EM), 
tetracycline (TC), chloramphenicole (CL) and trimethoprim -sulphametoxazole (TS). Penicillin, 
ceftriaxone and chloramphinicol are bactericidal and the remaining were bacteriostatic. The 
above minimum inhibitory concentration (MIC)  results were interpreted according to the 
European committee on antimicrobial Susceptibility testing  guideline (53). Pneumococcal 
isolates with clear inhibition zone of ≤ 0.06 µg/ml of penicillin  indicates susceptibility to 
penicillin and pneumococcal isolates of MIC ≥ 0.12  µg/ml ≤ 2 µg/ml as intermediate resistant 
and > 2 µg/ml are resistant for penicillin. Ceftriaxone pneumococcal isolates with MIC of ≤ 0.5 
µg/ml and are susceptible and > 2 µg/ml are resistant. Erythromycin pneumococcal isolates with 
MIC ≤ 0.25 µg/ml are suceptible and > 0.5 µg/ml are resistant. Tetracycline pneumococcal 
isolates with MIC ≤ 1 µg/ml are suscptible and > 2 µg/ml are resistant. Chloramphinicol 
pneumococcal isolates with MIC ≤ 8 µg/ml are susceptible and > 8 µg/ml are resistant. 
Trimethoprim sulphamethoxazole pneumococcal isolates with MIC ≤ 1 µg/ml are susceptible 
and > 2 µg/ml are resistant  (50).  All E-test products were from Biomērieux.  
  
3.8.3. Quality-control procedures 
Standard strain of S.  pneumoniae  ATCC 49619 and TIGR 4 were run in parallel to check the 
performance of the medium and potency of antibiotics. This quality control was done for every 
batch of media. 
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3.8.4 Serotyping 
All culture positive pneumococcal isolates were tested by the Quellung reaction using serotyping 
sera from Staten Serum Institute (SSI), 
 
Copenhagen,  Denmark. First pool antisera from A-I 
containing all serogroups and serotypes in one bottle were used followed by group and typing 
sera until the final serotype  was determined.   Serotyping test was performed by taking a 0.5µl 
platinum loopful of normal saline and suspending a pure colony in the saline with enough 
concentration. Then a loopful of antisera was added. The test was considered positive if swelling 
and clumping of cells was observed under the microscope. If the test was positive for one of the 
pool antisera,  then testing again for groups and types included in that pool of antisera was 
further tested. When a type was obtained, testing was stopped but for groups factor sera were 
used to determine the type (11).  
3.8.5. DNA preparation for MLST 
100 µl of phosphate buffer saline (PBS) buffer was dispensed in an Eppendorf  tube and 1 µl 
loop of pure colony was suspended  in the buffer. After boiling at 100
o
C in a dry bath for 10 
minutes and  centrifugation at 13000 rpm for 5 minutes,  the supernatant was transferred to 
another clean Eppendorf  tube. The tubes were stored at -20
O
 C until further testing.  
Using the seven housekeeping genes primers listed in the table3 below, with a concentration of 
10 µM the target genes were amplified followed by cleaning to get pure products. Then 
sequencing of the PCR product was performed using the same primers with a concentration of  
1.6 µM.  All procedures were performed using Eppendorf  robot, automatically cleaning 
repeatedly followed by sequencing at Applied Biosystem sequencing machine. The primers of 
these genes are as follows for up and down strands.  
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Table 3  Primers used for MLST 
Gene Name Primer 
name 
Primer sequence  
aroE  shikimate dehydrogenase aroE-up 
aroE-dn,  
5'-GCC TTT GAG GCG ACA GC 
 5'-TGC AGT TCA (G/A)AA ACA T(A/T)T TCT 
AA  
gdh  
 
glucose-6-phosphate 
dehydrogenase 
gdh-up  
gdh-dn 
5'-ATG GAC AAA CCA GC(G/A/T/C) AG(C/T) T 
5'-GCT TGA GGT CCC AT(G/A) CT(G/A/T/C) CC  
gki  glucose kinase gki-up 
 
gki-dn 
5'-GGC ATT GGA ATG GGA TCA CC  
5'-TCT CCC GCA GCT GAC AC 
recP  transketolase recP-up 
recP-dn 
5'-GCC AAC TCA GGT CAT CCA GG  
5'- TGC AAC CGT AGC ATT GTA AC  
spi  signal peptidase I spi-up 
spi-dn 
5'-TTA TTC CTC CTG ATT CTG TC 
5'-GTG ATT GGC CAG AAG CGG AA  
xpt  xanthine 
phosphoribosyltransferase 
 xpt-up 
xpt-dn 
5'-TTA TTA GAA GAG CGC ATC CT  
5'-AGA TCT GCC TCC TTA AAT AC 
 ddl  D-alanine-D-alanine 
ligase 
ddl-up                                         
ddl-dn 
5'-TGC (C/T)CA AGT TCC TTA TGT GG  
5'-CAC TGG GT(G/A) AAA CC(A/T) GGC A 
 
Finally the resulting  sequence type (ST) was interpreted by interring the result into the Bacterial 
Isolate Genome Sequence Database (BIGSdb)  software  for each of genes and sequence type 
identified for all pneumococcal isolates. (15, 48, 49)  
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3.8.6. Real- Time PCR (RT - PCR) 
 
CSF samples which were negative by culture were tested using real time PCR (14). The CSF 
were cleaned by Qiagen cleaning solution QIAamp 
®
 DNA mini kit, Qiagen staring 200 µl CSF 
finally 50 µl of ready to run clean sample and stored at -20
o
C.  
Table 4 RT PCR reagents and their proportion 
Reagent  Volume  Final concentration  
TaqMan Fast Universal PCR Master MIX  10 µl 1x 
Nm,  primer   ctrA-F  0.6 µl 300 nM 
       primer   ctrA-R  0.6 µl 300 nM 
       probe ctrA-P  0.8 µl 200 nM 
Hi,  primer omp P2-F  0.4 µl 200 nM 
      Primer omp P2-R  0.4  µl 200 nM 
      probe omp P2-P  0.8 µl 200 nM 
Spn,  primer F373  0.4µl 200 nM 
         Primer R424   0.4 µl 200 nM 
         probe pb400 Cy5  0.8 µl 200 nM 
10x Exo IPC-mix  2 µl 1x 
50x Exo IPCDNA   0.4 µl 1x 
Nuclease free water  0.4 µl  
The cocktail was prepared according to the above proportion for one sample with final volume of 
reagent (n samples  x n parallels) + 3. The reaction volume in this procedure was 20 µl. 2 µl 
clean product and 18  µl of cocktail.  (Table 4) All samples were run with two parallels to avoid 
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false positives.  Using multiple real time (RT)-PCR primers 140 CSF samples were tested for the 
presence of N. meningitids, H. influenzae and S. pneumoniae DNA. CSF collected using plain 
tube were tested directly and CSF collected using TI media were dilute 1:50 with Nuclease free 
water.  Finally the reaction ran by a machine Applied bio system 7500 fast system. The reporter 
chromophor was FAM. (2) (Table 5). RT products with CI greater than 1 at both parallels 
considered as positive and positive only at a single parallel were re- assayed using three parallels 
to confirm. Annex 2  
Table 5 Primers and probes sequence used for Real time PCR  
Organism  Primer  Primer sequence  Probe 
N.meningitidis  Ctr A F 
Ctr AR 
5'TGTGTTCCGCTATACGCCATT 
GCCATATTCACACGATATACC 
Ctr A-P  
5' ACCTTGAGCAA"T"CCATTTA 
TCCTGACGTTCT 
S.pneumoniae Lyt A F373 
Lyt A R424 
5'ACGCAATCTAGCAGATGAAGCA 
5' TCGTGCGTTTTAATTCCAGCT 
Pb 400Cy5  
5' FAM 
GCCGAAAACGC”T”TGATAC 
AGGGAG BHQ1 
H.ifluenzae Omp 2-F 
Omp 2 -R 
5'GGTTAAATATGCCGATGGTGTTG 
5' TGCATCTTTACGCACGGTGTA 
Omp P2-P 
5'TTGTGTACACTCCGT"T"GGT 
AAAAGAACTTGCAC 
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Table 6. Real time program 
Procedure Temprature Time Total  
Denaturation  95
o
C 20'sec  
45 cycles Annealing 60
o
C 30' sec 
Extension  60
o
C 30' sec 
Cooling  4
o
C ∞  
 
 
3.9.  Data management 
Demographic and all microbiological, serological and molecular data were recorded 
electronically using  Microsoft - Excel sheet to be retrieved by electronic copy in computer as 
well as with memory sticks for back up. The investigator was conducting periodic record audit at 
microbiology laboratories in order to check missed data comparing the hard copy of laboratory 
log books.  The data were kept confidential for third party.   
 
  3.10. Statistical analysis 
All recorded data were transferred from excel to SPSS version 20. From these used to prepare 
descriptive statistics and frequency tables and figures.    
3.11.  Ethical clearance   
Ethical clearance was obtained from the Norwegian Ethical Review Board (REK) and the  
Scientific and Ethical Review Office at EHNRI. (Annex 3 and 4) Since samples were not 
collected for purpose of  this study, consent or assent form was not mandatory. Instead for this 
study we have used the left over samples for the conformation of suspected causative agent. 
 
 
 
 
25 
 
4.12. Plan for the project 
Table 7  Project timeline for the master's project 
Activity Time  
Protocol writing April 2012 - June 2012 
Submiting the protocol to REK June 2012 
Ethical aproval from SERO/EHNRI July 2012 - September 2012 
Sample collection from the study sites and laboratory 
analysis /EHNRI 
September 2012 - December 2012 
Material transfer to NIPH January 2013 
Laboratory analysis /NIPH February 2013 - April 2013 
Data analysis and thesis write up  April 2013 - May 2013 
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Chapter four:   Results 
4.1 Patient characteristics  
A total of 460 patients were included in the study. (Table 8) The gender ratio was 1:1 with 232 
(50.5%)  males and 228 (49.5%) females. The age distribution was from 4 month up to 51 years 
old with the mean age of 15. Of the 460 clinical samples, 265 were collected from pediatric 
patients under five years old; 228 (49.5%) were collected from invasive cases (sterile body sites)  
and 232 (50.5%)  from non invasive (non sterile body sites) cases.  
 
Table 8 Sample types and collection sites from Ethiopia 
Sample 
type 
Black 
Lion 
Yek12 St. 
Paul 
Addis 
Ketema 
Woreda7 Gondar Selam EHNRI Total 
CSF 33 76 - - - 98 - 12 219 
Blood  1 - - - - - - - 1 
Throat 
swab  
- - 3 - 1 - 37 1 42 
Sputum - - 98 39 25 - 14 2 179 
Pleural 
fluid 
1 - 8 - - - - - 9 
Ear 
swab 
- - 4 - - - - 6 10 
Total 35 76 113 39 26 98 51 21 460 
 
The CSF samples (219) predominated,  followed by sputum (179), throat (42), ear (10) and 
pleural fluid (8). Only one blood sample was included in the study. More specimens were 
collected from St.  Paul Hospital followed by Gondar University Hospital and Yekatit 12 
Hospital.  
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Figure 3 Bar chart age group of patients from Ethiopia with gender. 
 
The ratio of male and female patients was similar in all age groups, except in the infant age 
group where the number of females outnumbered  males. On the other hand in adult age groups 
the number of female outnumbered. (Figure 3) 
 
 
 
 
 
 
28 
 
4.2  Culture result  
 
 
  Table 9  Type of samples and their culture result 
Sample                                  Culture Total 
Negative Percent Positive Percent 
Sputum 172 96% 7 4% 179 
Throat 25 59% 17 41% 42 
CSF 196 89% 23 11% 219 
Pleural 5 56% 4 44% 9 
Blood 0  1  1 
Ear 1 10% 9 90% 10 
Total 399  61  460 
 
Out of  the 460 samples, 61 were culture positive  (Table 9).  The pneumococcal culture positive 
rate was 61/ 460  (13%).  These included 28 (45%) samples from invasive diseases and 33  
(55%) from non invasive diseases. The highest number of pneumococcal culture positive was 
observed in  CSF samples,  followed by throat samples and ear samples.  According to the 
proportion of samples,  ear swab, pleural fluid  and throat samples have higher positive rate of 
pneumococcus 90%, 44% and 41%,  respectively. 
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Table 10 Culture result according to age  
Age group Culture  Total  
Positive  Negative  
<1 0 4 4 
1 0 22 22 
2-4 28 181 209 
5-14 15 3 18 
15-29 6 92 98 
30-44 6 78 84 
45 and above  7 18 25 
Total  61 399 460 
 
The culture positive rate was higher in children less than 14 years of age, 43 /61  (70%) 
pneumococcal isolates were from this age group. Most of the pneumococcal isolates due to 
invasive cases (isolates from sterile sites) were from this age group  24/28  (86%).  In this study 
infant age groups (<1 years of age) have no pneumococcal findings  (Table 10).  
 
 
 
 
 
 
 
30 
 
4.3  Serotype result 
 
 
Figure 4 Pneumococcal serotype distribution from patients in Ethiopia 
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Of the 61 samples positive for pneumococci in culture, 6 samples from  non invasive diseases 
harbored multiple serotypes : these were 4 throat samples, 1 sputum and 1 ear swab. In addition, 
one 19F and one NT strain were recovered from one CSF sample. (Table 11) The total number of 
isolates became 68.  
Table 11 Multiple serotypes and their sources 
Multiple serotypes Source STs  
1 + NT Throat 1(217)  & NT(2711) 
27 + NT Throat 27(1475) & NT (1475) 
27 + NT Throat 27(1475) & NT(1475) 
14 + 18F Sputum 14 (63)  &  
19F + NT CSF 19F(1203)  &NT(1203) 
19F + NT Ear 19F(1203) &NT(1203) 
20 + 1 Throat 20(6451) & 1(303) 
 
In this study 16 serotypes were identified and serotype 1 was the leading cause of 
pneumococcal infection,  followed by serotypes 19F and 20. Serotypes 14 and 27,  non typable 
serotypes,  19A,  18F,  5,  7C and  8 and 10,  13, and  22A, and 15, and 46 have their own  
contribution.  All serotypes were isolated from CSF except 18F, 7C, 13, 15C and 46 which 
were only isolated from non invasive (non sterile) sites. Serotype 1 was isolated from all types 
of clinical samples, except ear swab. (Table 12)  
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Table 12 serotype distribution according to site of isolation   
 
Serotype Frequency Site of isolation  
CSF Throat Ear Sputum  Pleural  Blood  
1 14 5 4 0 2 2 1 
19F 7 3 2 2 0 0 0 
20 7 3 1 3 0 0 0 
14 6 3 0 0 3 0 0 
27 6 1 3 0 0 2 0 
NT 5 1 3 1 0 0 0 
19A 3 2 1 0 0 0 0 
18F 3 0 2 0 1 0 0 
5 3 1 1 1 0 0 0 
7C 3 0 1 0 1 0 0 
8 3 1 1 1 0 0 0 
10A 2 2 0 0 0 0 0 
13 2 0 1 0 1 0 0 
22A 2 1 0 0 0 0 0 
15C 1 0 0 1 0 0 0 
46 1 0 0 1 0 0 0 
Total 68 23 20 10 8 4 1 
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4.4 Antimicrobial susceptibility  
Table 13.  MIC results of the 68 pneumococcal isolates 
Antibiotics                             MIC in µg/ml           
0.0
16 
0.032 0.064 0.125 0.250 0.5 1 2 4 8 16 32 
Penicllin G 21 23  5 12 4 3      
Ceftriaxone 37 12 4 5 6 3     1  
Erythromycin  4 10 45    3 4 1 1  
Tetracycline   2 42 6   1  2 7 8 
Chloramphenicol        37 28   3 
Trimethoprim- 
sulphamethoxazole 
   3 17 23  4 7 3  4 7 
 
The susceptibility pattern of pneumococcal isolates were interpreted from Table 13.  
 
 
 
Table 14 Antibiotics and their result 
Antibiotics Susceptible Intermediate  Resistant 
Penicillin  44 24 0 
Ceftriaxone 67 0 1 
Erythromycin 59 0 9 
Tetracycline 50 1 17 
Chloramphenicol 65 0 3 
Trimethoprim- 
sulphamethoxazole 
43 4 21 
 
 
 
34 
 
Of the 68 pneumococcal isolates 44 were susceptible for penicilin and 24 were intermediate  
resistant. Thirteen CSF  isolates were susceptible for penicillin and the remaining were 
intermediate resistant. All  but one pneumococcal isolates were susceptible to ceftriaxone; the 
resistant  isolate was from ear swab. Nine isolates were resistant to erythromycin; those were 3 
from CSF, 3 from throat, 1 from blood, 1 from ear and 1 from pleural fluid. Fifty pneumococcal 
isolates  were susceptible to tetracycline, 1 was intermediate resistant and 17 were resistant (9 
from CSF, 1 pleural, 1 blood and the remaining ones from non invasive sites). Three isolates 
were resistant to chloramphenicol, 1 from CSF, 2 from throat samples. Four isolates were 
intermediate resistant to trimethoprim - sulphamethoxazole  and 21 resistant (11 from CSF, 1 
from pleural fluid and the remaining ones were from non invasive  (Table 14) .  In this study 
there is no significance difference in susceptibility pattern between pneumococcal isolates of 
invasive and non invasive diseases.  
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4.5. Multilocus sequence typing results 
Table 15 Result of sequence typing for 68 pneumococcal isolates from Ethiopia 
Sequence type (ST)  Frequency Serotypes  
63 6 14 
217 8 1 
289 3 5 
303 2 1 
1203 9 19 F = 7  and NT=2  
1475 8 27 = 6   and NT= 2  
2054 3 7C 
2345 3 19A 
2711 4 18F = 3 and NT = 1 
6451 7 20 
8873 2 22A 
8874 3 8 
8875 2 13 
8876 2 10A 
8877 4 1 
8974 1 15C 
8975 1 46 
 
All the data from the seven housekeeping genes were entered into the software and analyzed.  
After summing up all results of the seven housekeeping genes 17 STs  were identified, of which 
7 were new  (8873, 8874, 8875, 8876, 8877, 8974 and 8975).  Out of the seven multiple 
serotypes four of them were the same clone,  three of them were different serotypes and different 
clones. (Table 15).  
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Table 16 ST associated with source of sample from patients in Ethiopia 
 
ST Sample  
CSF Throat Ear Sputum Pleural  Blood 
63 
3 0 0 3 0 0 
217 
2 2 0 2 2 0 
289 
1 1 1 0 0 0 
303 
1 1 0 0 0 0 
1203 
3 2 2 0 0 0 
1475 
1 5 0 0 2 0 
2054 
0 2 0 1 0 0 
2345 
2 1 0 0 0 0 
2711 
0 2 0 1 0 0 
6451 
3 1 3 0 0 0 
8873 
2 0 0 0 0 0 
8874 
1 1 1 0 0 0 
8875 
0 1 0 1 0 0 
8876 
2 0 0 0 0 0 
8877 
2 1 0 0 0 1 
8974 
0 0 1 0 0 0 
8975 
0 0 1 0 0 0 
 
 
Some STs  are isolated from multiple samples as well as invasive and non invasive samples. 
Fifteen pneumococcal isolates were from the new alleles and 8 from invasive diseases and 7 of 
them were from non invasive. Out of the new STs 2 of them were only from invasive cases, 3 
from non invasive and 2 from both sites.    
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4.6 Vaccine coverage 
Out of serotypes identified by this study 4 serotypes of PCV-10 and 5 serotypes of PCV-13 are 
found.  
Table 17 Vaccine coverage of serotypes from Ethiopia 
 
Vaccine  Coverage total 
(n=68) 
Coverage invasive (n=28) 
PCV-10(1.5,14,19F) 44% 45% 
PCV-13(1.5,14,19F,19A) 49% 52% 
 
The main target of vaccine is for the prevention of invasive diseases and if we consider invasive 
isolates independently, the vaccine coverage will be 45% and 52% for PCV-10 and PCV13 
respectively. non vaccine serotypes 
4.7  Real Time PCR results 
Table 18  Result of 140 culture negative CSF from Ethiopia 
Organism Frequency 
S. pneumoniae 9 
N. meningitidis 12 
S. pneumoniae + N. meningitidis 1 
S. pneumoniae + H. influenzae 1 
Negative 117 
Total 140 
 
In this study 140 culture negative CSF were run by RT-PCR and 23 of them were positive for 
meningitis agents.  N. meningitidis were the leading agent (n=12) followed by S. pneumoniae 
(n=9) and two samples were positive for multiple agents one with S. pneumoniae + N. 
meningitidis and S. pneumoniae + H. influenzae. (Table 18) 
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Table 19 RT-PCR result according to study sites 
Study site Isolate 
Spn Nm Hi Nm + Spn Spn + Hi 
Gondar University Hospital 6 10 0 1 1 
Black Lion Hospital 3 1 0 0 0 
Yekatit 12 Hospital 0 1 0 0 0 
 
Most of RT-PCR positive results (n=18) were from Gondar University Hospital followed by 
Black Lion Hospial and 1 from Yekatit 12 Hospital. Mixed results were also from the more 
positive study site; it might be due to contamination at the laboratory or sample collection.  
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Chapter 5 Discussion  
5. 1  Sample collection 
Pneumococcus has a great public health importance worldwide due to its medical impact up on 
the society. The main burden of  the bacterium are its multiple infections followed by high 
mortality rate, complications after cure, resistance to empirical antibiotics, as well as variation 
among strains circulating in a given community. The fatality and prevalence of the organism is 
higher relative to other similar agents for a specific disease  (51). It is vaccine preventable 
disease and currently different types of vaccines that have great impact for the reduction of its 
burden are produced.  Since the vaccine is serotype specific, prior to or the introduction of 
vaccine, information about pneumococcal serotypes circulating in the community is mandatory.  
Otherwise the effect of the vaccine will be difficult to evaluate  (52).  
 The aim of this study was to characterize pneumococcal isolates circulating in Ethiopia by 
taking clinical samples from patients including all age groups. A total of 460 clinical samples 
were collected from  228 invasive (sterile body sites) and 232 non invasive cases almost with 1:1 
ratio. Including both types of pneumococcal cases  will have good advantage identifying carriers 
and diseased individuals as well as identifying serotypes that can cause fatal cases.  A study 
conducted in Niger for the determination of pneumococcal serotypes, a total of 19, 223 CSF 
were collected all over the country, in 8 years surveillance.(53)  The time available for this study 
(6 months) prevented a more extensive and focused study.   
5.2  Culture results 
The general culture positive rate in this study was around 13% (61/460). Specifically for each 
type of samples, CSF had around 11% (23/219)  but other studies suggested that CSF culture 
among suspected meningitis case, the positive rate would be  around 16% ( 54)but in this study 
the rate was very low.  These samples were negative for other meningitis causing agents. The 
culture detection rate was low and it might be due to other confounding factors (prior antibiotic 
treatment, other meningitis agents, clinical criterias to diagnose for bacterial meningitis). In this 
study all samples were left over samples and we have no information about these factors. Most 
of CSF samples were clear indicating that non pyogenic meningitis and all meningitis agents 
other than bacteria were not addressed in this study. Meningitis besides bacterial agents, can also  
be caused by viruses, parasites, and fungal elements (55). This might have its own contribution 
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for low detection rate. The rate of pneumococcal isolation is seasonal and collecting samples 
beyond the pick season also may reduce its yield.  All infant patients up the age of 12 months(1 
year ) were culture negative. This might be in part due to the introduction of PCV-10 vaccine in 
Ethiopia a year before. A study conducted in Israel similar to this study that after the introduction 
of 9- valent vaccine, the carriage rate was  reduced after the introduction of the vaccine  (56).  
The pneumococcal cases  (55%) were mainly between the age of 1 and 5 who are the vulnerable 
group for the agent.   
 
5.3  Antimicrobial susceptibility test results 
Penicillin G is the primary choice for the empirical treatment of pneumococcal infections  but in 
this study 35% (24/68) of the isolates were intermediate resistant for penicillin, but none were 
resistant. For  other bactericidal antibiotics (ceftriaxone and chloramphenicol)  all pneumococcal 
isolates were susceptible except one resistant for ceftriaxone and three for chloramphenicol.  
Bacteriostatic antibiotics erythromycine, tetracycline and trimethoprim-sulphametoxazole had  
resistance rate of 13% (9/68), 26.5% (18/68) and 37% 25/68 respectively. From meningitis cases 
46% (11/24) were resistant to penicillin while the 5 other invasive isolates (pleural and blood) 
were susceptible. Non invasive isolates had a higher resistance rate, especially throat followed by 
sputum isolates. A study conducted in Gondar Ethiopia, nasopharyngeal carriage and 
antimicrobial susceptibility pattern, the susceptibility pattern of isolates is similar except more 
penicillin resistant isolates in this study (57). Studies conducted  in West Africa, the Gambia and 
Kenya  show that there is significance increment of resistance rate in bactericidal antibiotics (17, 
18).   
 
5.4  Serotype results 
 Identifying pneumococcal isolates either at invasive or non invasive cases is important 
determining serotypes circulating in the community for preventive and epidemiological aspects.  
In this study, from both invasive and non invasive cases a total of 16 serotypes were identified 
including non typable. Serotype 1 was the leading cause of pneumococcal infection followed by 
19F and 20 serotypes among Ethiopian patients. This study agrees with  similar studies 
conducted  in the Gambia, West Africa  and Kenya, East Africa showing that serotype 1 is the 
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leading cause of pneumococcal infection in Africa (18, 58). Non typable isolates were identified 
from non invasive clinical samples. One non typable isolate  was identified from CSF together 
with 19F isolate. Both isolates had the same ST and  it might be that the organism could lose its 
capsule and  become non typable  (58).  But other serotypes most common in the above 
studies(6A, 6B,  23F) were not encountered by this study.  Out of the PCV-10 serotypes  only 4 
of them (1, 5, 14 and 19F) were included in this study whereas 5 (1, 5, 14, 19F and 19A) 
serotypes of PCV 13 were also included in this study. Considering invasive pneumococcal 
isolates, the vaccine coverage for PCV-10 and PCV-13 would be 45% and 52% respectively. 
Unless there is cross reaction between group serotypes the current PCV vaccines coverage is 
minimal for serotypes identified in this study. 
5.5 MLST results 
MLST is used to identify the similarities between isolates using housekeeping genes which are 
common for all clinical isolates. The data is used to classify pneumococcal isolates according to 
the degree of relation among serotypes for molecular epidemiology. In this study 17 STs were 
identified among the 61 isolates and out of these 7 STs were identified in this study. It is a 
significant contribution of new data on STs from a country with no previous data.   
5.6  CSF RT-PCR results 
RT-PCR has a high sensitivity and specificity identifying bacterial pathogens from clinical 
samples. The method has high sensitivity detecting up to a single DNA molecule (2). In this 
study 140 culture negative CSF were tested for the presence of bacterial pathogens, N. 
meningitidis, H. influenzae and S. pneumoniae  (14, 59).  Out of 140 culture negative CSF 
samples, 23 were positive for meningitis associated agents and two of them were mixed agents. 
Identifying mixed organisms from the very sterile sites is rare and it might be due to 
contamination during sample collection or laboratory analysis since these mixed organisms from 
the same study sites. Care should be taken to assure good quality of samples for such sensitive 
analysis as RT-PCR.  
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5.6 Conclusion  
In this study 15 serotypes of S. pneumoniae  were identified and only four and five of them were 
included  in the current vaccines PCV-10 and PCV-13,  respectively. The remaining serotypes 
were from non vaccine groups. The current vaccine in Ethiopia is PCV-10 and if this study was 
considered as background for the current vaccine, 44% coverage would be expected which is 
below the minimum desirable coverage.  
 
5.7 Recommendation 
A good vaccine should cover of more than 80% of the strains  circulating in the community. Due 
to this the vaccine already introduced in the immunization program should be validated with 
current findings on pneumococcal serotypes. Even according to this study the PCV-10 vaccine 
coverage is not good enough to be continued in the immunization program. 
Another enhanced pneumococcal surveillance should be performed with large number of 
samples using this study as a background.   
Susceptibility of isolates to antimicrobials which are prescribed in the health facilities should be 
checked in microbiology laboratory prior to empirical treatment.  
Awareness should be created among community members in order to avoid self prescription of 
antibiotics,  especially oral administered ones.  
Quality control should be routine part of the laboratory. 
All events in the laboratory should be recorded to trace unexpected through daily practices.  
Refreshment training is mandatory to have current practices about the subject matter globally. 
Sensitive laboratory methods should be part of diagnosis at least at the referral level.  
Better to introduce good laboratory practice at any procedure, to prevent contaminations incan 
prevent  
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5.8 Strong sides of the study. 
- Good quality control measures were followed throughout the study and many laboratory 
parameters were included which can be supplemental for each other.  
- Current and validated laboratory procedures were followed in well equipped and accredited 
laboratory.  
- Results were compared by senior laboratory personnel.  
5.9 Limitations of the study. 
- Duration of the study is short in order to include seasonal incidence of pneumococcal infection.  
- Seasonal variation of circulating serotypes were not identified.  
- Even though it is better relative to previous studies in Ethiopia still the number of isolates are 
not good enough to generalize for the country.   
- Study sites are so small relative to the total population of the country.  
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 Annex 1 General information of pneumococcal isolates from Ethiopia 
Supplement Table  
Isolate  Clinical 
source 
Study site Age  Sex Serogroup Sequence 
type 
1 Ear EHNRI 6 Female 20 6451 
2 CSF EHNRI 4 Male 5 289 
3 Ear EHNRI 7 Male 20 6451 
4 CSF EHNRI 5 Male 14 63 
5 CSF EHNRI 4 Female 1 217 
6 Ear EHNRI 3 Male 8 8874 
7 Throat EHNRI 16 Male 19F 1203 
8 Ear EHNRI 7 Male 20 6451 
9 CSF EHNRI 4 Female 14 63 
10 CSF EHNRI 6 Female 14 63 
11 CSF EHNRI 3 Female 20 6451 
12 CSF EHNRI 5 Female 20 6451 
13 CSF EHNRI 7 Male 20 6451 
14 CSF EHNRI 5 Male 1 303 
15 CSF EHNRI 4 Male 22A 8873 
16 CSF EHNRI 6 Male 22A 8873 
17 CSF EHNRI 4 Female 19F 1203 
18 Sputum Addis 
Ketema 
29 Female 14 63 
19 Sputum Addis 
ketema 
38 Female 1 217 
20 Throat Wereda 7 32 Female 5 289 
21 Sputum St. Paul 32 Female 13 8875 
22 Ear St Paul 12 Male 5 289 
23 Ear St Paul 11 Male 19F 1203 
24 Ear St Paul 13 Male 19F 1203 
25 Throat St Paul 16 Male 13 8875 
26 Throat St Paul 15 Male 18F 2711 
27 Sputum St Paul 45 Male 18F 2711 
28 Sputum St Paul 35 Male 14 63 
29 Pleural 
fluid 
St Paul 31 Male 27 1475 
30 Sputum St Paul 46 Female 1 217 
31 Throat Sealm 
Health 
Center 
2 Male 1 217 
32 Pleural Black Lion  21 Male 1 217 
33 Throat Sealm  2 M 27 1475 
34 Throat Sealm  3.2 M 1 303 
35 Throat Sealm  3 Female 18F 2711 
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36 Throat Sealm  2.8 Male 19F 1203 
37 Throat Sealm  4 Male 27 1475 
38 Throat Sealm  3 Female 8 8874 
39 Throat Sealm  4.6 Female 27 1475 
40 CSF Black Lion 4 Female 27 1475 
41 CSF Black Lion 3 Male 8 8874 
42 Pleural St. Paul 34 Male 27 1475 
43 Sputum St.Paul 14 Male 7C 2054 
44 Pleural St. Paul 21 Female 1 217 
45 Throat Selam 2.5 Female 7C 2054 
46 Throat Sealm 3.6 Female 19A 2345 
47 Throat Selam 4.8 Male 7C 2054 
48 Throat Selam 5 Feamle 1 217 
49 Throat Sealm 1.9 Male 1 8877 
50 CSF Gondar 4 Male 10A 8876 
51 CSF Gondar 3 Female 10A 8876 
52 CSF Gondar 4 Male 1 8877 
53 CSF Gonadr 1.5 Female 1 217 
54 CSF Gondar 2 Female 19F 1203 
55 CSF Gondar 3 Female 19F 1203 
56 CSF Black Lion 4 Female 19A 2345 
57 CSF Black Lion 3 Female 19A 2345 
58 Blood Black Lion 5 Female 1 8877 
59 CSF  Black Lion 3.5 Male 1 8877 
60 Ear EHNRI 5 Male 46 8975 
61 Ear EHNRI 3 Male 15C 8974 
62 CSF EHNRI 4 Female Non Typable 1203 
63 Sputum St.Paul 45 Male 14 63 
64 Ear St.Paul 11 Male Non- 
Typable 
1203 
65 Throat Selam 3.2 M 20 6451 
66 Throat Selam 2 M Non- 
Typable 
1475 
67 Throat Selam 4 M Non- 
Typable 
1475 
68 Throat Selam 2 M Non- 
Typable 
2711 
       
       
 
 
 
 
 
 
54 
 
Annex 2  Sample of Real Time PCR assay 
Run_20130322_ID_NmHiSpn_Surafel_65_74_results 
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Annex 5 Material Transfer Agreement (MTA) 
MATERIAL TRANSFER AGREEMENT 
 
From 
The Ethiopian Health and Nutrition Research Institute (EHNRI), Addis Abeba, Ethiopia 
(herein referred to as ENHRI) 
Represented by Dr. Almaz Abebe 
To 
WHO Collaborating Centre for Reference and Research on Meningococci, Division of Infectious 
Disease Control, Norwegian Institute of Public Health (NIPH), P.O.Box 4404 Nydalen, N-0403 
Oslo, Norway (herein referred as the RECIPIENT) 
Represented by Prof. Dominique A. Caugant 
Materials: 
Clinical specimens and pneumococcal isolates collected for the project entitled: 
“Characterization of pneumococcal isolates from patients in Ethiopia.” 
The Materials are provided to the RECIPIENT subject to the following terms and conditions: 
1. The Materials are provided as a service to the research community and are to be used 
under the immediate and direct control of the RECIPIENT to determine the serotype, 
antibiotic resistance pattern, and characterize the molecular variations of pneumococcal 
strains causing disease in Ethiopia. 
2. The Materials are not to be used: (a) in any product, (b) for the purpose of producing any 
product, or (c) for providing any service in which a product or service is sold or 
otherwise made commercially available. The Materials cannot be used for any other 
purpose without prior written consent of EHNRI. 
 
3. The Materials are not to be made available to any other entity or researcher outside NIPH 
without prior written consent of EHNRI.  
 
4. The source of the Materials should be acknowledged in any presentation or publication 
for which the Materials are used. 
 
5. The Materials will be used in compliance with all applicable statutes and regulations, 
including regulations related to the disposal of hazardous materials. 
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